Yang Chen, Gail J Harty, Ye Zheng, Seethalakshmi R Iyer, Shinobu Sugihara, S Jeson Sangaralingham, Tomoko Ichiki, Joseph P Grande, Hon-Chi Lee, Xiaoli Wang, John C Burnett
RATIONALE: Acute kidney injury (AKI) has a high prevalence and mortality in critically ill patients. It is also a powerful risk factor for heart failure incidence driven by hemodynamic changes and neurohormonal activation. However, no drugs have been approved by the Food and Drug Administration. Endogenous pGC-A (particulate guanylyl cyclase A receptor) activators were reported to preserve renal function and improve mortality in AKI patients, although hypotension accompanied by pGC-A activators have limited their therapeutic potential...
May 10, 2019: Circulation Research